Piper Sandler Reaffirms “Overweight” Rating for AtriCure (NASDAQ:ATRC)

AtriCure (NASDAQ:ATRC)‘s stock had its “overweight” rating restated by Piper Sandler in a research note issued on Wednesday, Benzinga reports. They presently have a $70.00 price target on the medical device company’s stock, up from their previous price target of $60.00. Piper Sandler‘s price target suggests a potential upside of 8.60% from the company’s previous close.

Several other equities analysts have also recently issued reports on ATRC. Stifel Nicolaus set a $65.00 price objective on shares of AtriCure in a research note on Thursday, September 17th. Freedom Capital lowered shares of AtriCure from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. Citizens Jmp raised their target price on shares of AtriCure from $52.00 to $68.00 and gave the stock a “market outperform” rating in a report on Wednesday, October 21st. Weiss Ratings upgraded shares of AtriCure from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, October 8th. Finally, Zacks Research cut AtriCure from a “strong-buy” rating to a “hold” rating in a report on Monday, August 24th. Six equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $58.00.

AtriCure Price Performance

ATRC stock traded up $4.04 during trading hours on Wednesday, hitting $64.45. 473,347 shares of the stock traded hands, compared to its average volume of 870,469. The stock has a 50-day simple moving average of $56.03 and a 200 day simple moving average of $38.40. AtriCure has a one year low of $25.36 and a one year high of $64.96. The company has a market cap of $3.28 billion, a P/E ratio of 307.90 and a beta of 1.23. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Tuesday, November 3rd. The medical device company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.06) by $0.23. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The firm had revenue of $154.45 million for the quarter, compared to analysts’ expectations of $151.05 million. Equities analysts forecast that AtriCure will post 0.29 earnings per share for the current year.

Insider Buying and Selling

In other AtriCure news, Director Regina E. Groves sold 5,313 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $54.22, for a total value of $288,070.86. Following the transaction, the director owned 34,546 shares in the company, valued at approximately $1,873,084.12. This represents a 13.33% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Karl S. Dahlquist sold 9,370 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $48.89, for a total transaction of $458,099.30. Following the completion of the sale, the insider owned 87,319 shares of the company’s stock, valued at approximately $4,269,025.91. The trade was a 9.69% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 30,622 shares of company stock valued at $1,626,003. Corporate insiders own 4.00% of the company’s stock.

Institutional Trading of AtriCure

Several hedge funds and other institutional investors have recently modified their holdings of ATRC. BlackRock Inc. acquired a new stake in AtriCure during the second quarter valued at $125,198,000. Bank of America Corp DE acquired a new position in AtriCure in the 2nd quarter worth about $24,465,000. Grandeur Peak Global Advisors LLC acquired a new position in AtriCure in the 2nd quarter worth about $16,435,000. Osterweis Capital Management Inc. purchased a new stake in shares of AtriCure during the 2nd quarter worth about $14,028,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of AtriCure during the 2nd quarter worth about $9,388,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

AtriCure News Roundup

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure reported Q3 earnings of $0.17 per share and revenue of $154.45 million, topping estimates of $0.01 per share and $151.05 million, respectively. The company also moved from a year-ago loss of $0.01 per share to a profit. AtriCure beats Q3 earnings and revenue estimates
• Positive Sentiment: Needham raised its price target from $64 to $70 and kept a Buy rating. BTIG also raised its target to $70, reflecting improved analyst expectations after the quarterly results. Analysts boost forecasts after Q3 results
• Positive Sentiment: The company projects 2026 adjusted EBITDA of $91 million to $94 million and is targeting completion of BoxX-NoAF enrollment by year-end. AtriCure outlook and enrollment update
• Neutral Sentiment: AtriCure’s 2026 revenue forecast of $606 million to $610 million is broadly in line with the cited FactSet estimate of $606.2 million. AtriCure revenue outlook

About AtriCure

AtriCure, Inc is a medical device company that develops and sells products for the surgical treatment of atrial fibrillation (AFib) and related conditions. Its technologies are designed to support cardiac surgeons and electrophysiologists performing tissue ablation, left atrial appendage management and other procedures intended to restore or maintain normal heart rhythm.

The company’s product portfolio includes the AtriClip device, which is used to exclude the left atrial appendage, along with surgical ablation systems such as the Isolator Synergy clamps and cryoablation products.